FDA Grants Orphan Drug Status to Gevokizumab

The FDA has granted orphan drug designation to gevokizumab for the treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis, or chronic noninfectious anterior uveitis.
Orphan Drug Approvals